TScan Therapeutics Inc TCRX
News
Trading Information
- Previous Close Price
- $4.97
- Day Range
- $4.90–5.08
- 52-Week Range
- $2.43–9.69
- Bid/Ask
- $4.84 / $5.34
- Market Cap
- $266.99 Mil
- Volume/Avg
- 170,490 / 347,185
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 41.24
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 188
- Website
- https://www.tscan.com
Comparables
Valuation
|
Metric
|
TCRX
|
KYTX
|
GTHX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.05 | 0.68 | 15.32 |
Price/Sales | 41.24 | — | 6.40 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TCRX
|
KYTX
|
GTHX
|
|---|---|---|---|
Quick Ratio | 7.72 | 14.75 | 1.97 |
Current Ratio | 7.77 | 14.86 | 2.48 |
Interest Coverage | −29.80 | −558.59 | −3.99 |
Quick Ratio
TCRX
KYTX
GTHX
Profitability
|
Metric
|
TCRX
|
KYTX
|
GTHX
|
|---|---|---|---|
Return on Assets (Normalized) | −32.50% | −37.69% | −29.58% |
Return on Equity (Normalized) | −54.73% | −76.90% | −94.76% |
Return on Invested Capital (Normalized) | −39.01% | −77.97% | −33.14% |
Return on Assets
TCRX
KYTX
GTHX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Fscfhfhwj | Vxlcw | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Rcqnhtkg | Mhdfqw | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Dvlmnnwf | Bsblj | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xjnysdpm | Xhgvs | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Lvtcblkf | Dmv | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Vpfsxvr | Hkth | $28.1 Bil | |||
| Moderna Inc
MRNA
| Vfzmhddt | Mbzw | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Fwprcjkz | Gcfgt | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Ddlfnvdtr | Lvnlpm | $13.4 Bil | |||
| Incyte Corp
INCY
| Cvggmgk | Rdkgf | $12.7 Bil |
United States